SecBot SecBot

LGVN

Longeveron Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001721484 Biotech & Drug Discovery
$2.14 −0.35 (−14.06%)
Nov 16 4:00 PM ET · prev $2.49
Market cap
$10.0M
Nano cap
Median target
$61.25
+2762% · range $42.50–80.00
1 year
−67.0%
from $6.49 · Nov 17
30 days
+54.0%
from $1.39
52-week range
$1.39–11.60
−82% from high · low Oct 16
Avg volume 20D
101.0K
Nov 10 spike 734.2K
Short interest
157.1K
≈4.9% of shares · +114.7%
Days to cover
2.2
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BEARISH 11 reports · 90 days
Balance 5 bearish · 1 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 9/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 4 added (0 new), 1 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.500 → −$1.700 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersBUILDING

    Short interest +114.7% to 157.1K shares. 2.2 days to cover, ≈4.9% of shares.

  • TrendRANGE

    24% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCDOUBLED1,353,881$951.8K
VANGUARD FIDUCIARY TRUST CODOUBLED140,127$98.5K
NORTHERN TRUST CORPDOUBLED43,299$30.4K
JONES FINANCIAL COMPANIES LLLPDOUBLED1,300$930.00
UBS Group AGNEAR_EXIT5$4.00
BlackRock, Inc.DOUBLED224,198$233.2K
GEODE CAPITAL MANAGEMENT, LLCADD203,618$211.8K
HRT FINANCIAL LPDOUBLED118,891$123.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action May 2026
12-month targets · 2 analysts

Price is below the lowest target. Median implies +2762%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
May 11, 2026Maxim Group
DOWNGRADE
DOWNGRADEHold
May 4, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 15, 2025Roth Capital
MAINTAIN
MAINTAINBuy
Mar 21, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 3, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Dec 5, 2024Roth MKM
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 1, 2026
Willard Stephen H
Chief Executive Officer
Oct 1, 2026
TAX W/H$5.1K
Oct 1, 2026
Agafonova Nataliya
Chief Medical Officer
Oct 1, 2026
TAX W/H$7.5K
Oct 1, 2026
Jhaveri Nirav S.
Chief Financial Officer
Oct 1, 2026
TAX W/H$1.9K
Oct 1, 2026
Blass Devin
CTO & SVP of CMC
Oct 1, 2026
TAX W/H$6.5K
Oct 1, 2026
Lehr Paul T
General Counsel, Secretary
Oct 1, 2026
TAX W/H$5.8K
Aug 19, 2026
Ascheim Deborah
Director
Aug 19, 2026
AWARD36,000 sh
Aug 19, 2026
Agafonova Nataliya
Chief Medical Officer
Aug 19, 2026
AWARD286,000 sh
Aug 19, 2026
Lehr Paul T
General Counsel, Secretary
Aug 19, 2026
AWARD286,000 sh

Earnings setup

Estimates
−$1.70
EPS estimate, this quarter
−13%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.70-$1.70–-$1.70+2.9%$900.0K
Next Q-$1.40-$1.40–-$1.40-21.7%$500.0K
Current FY-$7.20-$7.20–-$7.20+7.1%$1.8M
Next FY-$5.30-$5.80–-$4.80-7.4%$2.2M

Short side

FINRA· Oct 30, 2026
157,139
shares short
+114.7%
vs prior settlement
2.2
days to cover
≈4.9%
of shares outstanding
Trading halts
Sep 16, 2026Resumption ScheduledResumed
Aug 26, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Benjamin Matthew Wall Baggett filed a Schedule 13G disclosing beneficial ownership of 250,000 shares of Longeveron…
SC 13G · Impact 4/10
Nov 12, 2026 SEC
Longeveron reported Q3 2026 net loss of $6.1M ($1.91 per share) on revenue of $0.1M, missing the consensus EPS…
PRESS-RELEASE · Impact 6/10
Nov 12, 2026 Earnings
Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
Longeveron reports third quarter 2026 financial results and provides business update.
Oct 26, 2026 Press
Longeveron announced updated results from its Phase 2b ELPIS II trial of laromestrocel in HLHS. The trial missed the…
Impact 6/10
Oct 1, 2026 Insider
Willard Stephen H surrendered for taxes 1,987 shares
Chief Executive Officer @ $2.59 ($5.1K)
Oct 1, 2026 Insider
Agafonova Nataliya surrendered for taxes 2,913 shares
Chief Medical Officer @ $2.59 ($7.5K)
Oct 1, 2026 Insider
Jhaveri Nirav S. surrendered for taxes 742 shares
Chief Financial Officer @ $2.59 ($1.9K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

17 filings · 5 press releases · 1 bullish · 8 bearish · 8 neutral
All LGVN filing & press-release reports (22)